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Summary
 
Interleukin (IL)-9, a pleiotropic cytokine produced by the Th2 subset of T lymphocytes has
been proposed as product of a candidate gene responsible for asthma. Its wide range of biolog-
ical functions on many cell types involved in the allergic immune response suggests a poten-
tially important role in the complex pathogenesis of asthma. To investigate the contributions of
IL-9 to airway inflammation and airway hyperresponsiveness in vivo, we created transgenic
mice in which expression of the murine IL-9 cDNA was regulated by the rat Clara cell 10 pro-
tein promoter. Lung selective expression of IL-9 caused massive airway inflammation with
eosinophils and lymphocytes as predominant infiltrating cell types. A striking finding was the
presence of increased numbers of mast cells within the airway epithelium of IL-9–expressing
mice. Other impressive pathologic changes in the airways were epithelial cell hypertrophy as-
sociated with accumulation of mucus-like material within nonciliated cells and increased sub-
epithelial deposition of collagen. Physiologic evaluation of IL-9–expressing mice demonstrated
normal baseline airway resistance and markedly increased airway hyperresponsiveness to in-
haled methacholine. These findings strongly support an important role for IL-9 in the patho-
genesis of asthma.
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topic asthma is a chronic inflammatory disorder of the
airways associated with reversible airway obstruction
and bronchial hyperresponsiveness (1). The response to
antigen in the airways involves various types of inflamma-
tory cells, including eosinophils, B cells, mast cells, and
activated T cells, in particular CD4
 
1
 
 T cells of the Th2
subset (2, 3). Although the precise mechanisms of this re-
sponse are still unknown, there is evidence that complex
interaction between these cells leads to the production of
cytokines and other inflammatory proteins with important
impact in the pathogenesis of asthma (4, 5).
Genetic susceptibility to atopic asthma is thought to be
multigenic (6, 7). Although the gene(s) predisposing to
asthma, atopy, and bronchial hyperresponsiveness have not
yet been identified, various genetic studies in humans have
linked these characteristics to chromosome 5q31-q33 (8–
10). This chromosomal region contains several genes that
are implicated in bronchial inflammation associated with
asthma (11–13). Recently, one of them, IL-9, has been
suggested as a candidate gene for asthma (10, 14).
IL-9 is a T cell–derived cytokine with pleiotropic effects
on various cell types (15). IL-9 seems to be produced in
vitro and in vivo by CD4
 
1
 
 T cells, preferentially of the
Th2 subset (16–22). The in vitro biological functions of
IL-9 include its ability to stimulate proliferation of activated
T cells (23–25), to enhance production of immunoglobulin
in B cells (26, 27), and to promote proliferation and differ-
entiation of mast cells (28, 29) and hematopoietic progeni-
tors (30, 31). The involvement of IL-9 in lymphomagenesis
has been suggested by in vivo studies with transgenic mice
expressing IL-9 constitutively in which a higher suscepti-
bility to develop thymic lymphoma was observed (32).
The pleiotropic functions of IL-9 suggest a major role
for this cytokine in the complex immune response associ-
ated with allergic forms of asthma. To study in vivo poten-
tial contributions of IL-9 to the pathogenesis of asthma,
 
A
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we created transgenic mice that overexpress IL-9 selec-
tively within the lungs. We show that expression of IL-9
in the airway epithelium of transgenic mice results in air-
way inflammation, mast cell hyperplasia, and dramatically
increased airway hyperresponsiveness.
 
Materials and Methods
 
Production of Transgenic Mice.
 
The 443-bp murine IL-9 cDNA
(Genetics Institute, Cambridge, MA) was cloned as a XhoI–
EcoRI fragment into the NdeI–BglII sites of plasmid pCC10-
SV40 (33) using SalI–NdeI and EcoRI–BglII oligonucleotide
adapters. The resulting plasmid pCC10-IL9-SV40 was purified
from large scale cultures using the Plasmid Maxi Kit (QIAGEN,
Inc., Chatsworth, CA). After digestion of the plasmid with XhoI
and SacII, the CC10-IL9-SV40 transgene was separated by elec-
trophoresis through a 1% agarose gel (SeaKem GTG BioProducts,
FMC; Rockland, ME), isolated by electroelution, and then puri-
fied as previously described (33) before injection into (C3H 
 
3
 
C57BL/6) F2 eggs (34). Positive founder animals were identified
by Southern blot analysis of tail DNA using a 
 
32
 
P-labeled full-
length fragment of the murine IL-9 cDNA. Founder animals
were backcrossed onto strain B10.D2 (The Jackson Laboratory,
Bar Harbor, ME) and transgene-positive animals from subsequent
generations were identified by PCR analysis of tail DNA. PCR
was performed using the following primers to identify the IL-9
construct: 5
 
9
 
 CAT CCT TGC CTC TGT TTT GC 3
 
9
 
 (sense);
and 5
 
9
 
 CGT CCC CAG GAG ACT CTT C 3
 
9
 
 (antisense). Am-
plification of the inserted IL-9 cDNA was performed by 25 cycles
at 95
 
8
 
C, 60
 
8
 
C, 72
 
8
 
C for 1 min each to yield a IL-9 DNA product
of 379 bp that was detected by agarose gel electrophoresis. Trans-
gene-positive animals (heterozygous for the transgene) and their
transgene-negative littermates were analyzed between 6 and 12 wk
of age.
 
Lung Lavage, Tissue Fixation, and Staining.
 
Mice were anes-
thetized by methoxyflurane inhalation and killed by exsan-
guination or carbon dioxide inhalation. Blood was allowed to
clot at room temperature for 30 min and serum was recovered by
centrifugation (10,000 rpm, 5 min at 4
 
8
 
C), frozen on dry ice, and
stored at 
 
2
 
70
 
8
 
C until use. Lung lavage was performed by insert-
ing a cannula into the trachea and lavaging with three successive
aliquots of 1 ml PBS as previously described (33). Aliquots of la-
vage fluid were centrifuged and the supernatants were harvested
and stored individually at 
 
2
 
70
 
8
 
C until use. All measurements
were made on the first aliquot of lavage fluid (85–90% of the 1-ml
input volume was retrieved). Lavage cells were resuspended in
PBS and counted using a hemocytometer. Differential cell counts
were performed on cytospin cell preparations stained with Diff-
Quik (VWR Scientific Products, Bridgeport, NJ). Lungs were
then excised completely from the chest, inflated with 10% forma-
lin, and immersed in 10% formalin. Paraffin embedding, various
histological stainings, and immunostaining for 
 
a
 
-smooth muscle
actin of lung sections were performed by the Yale Medical
School Research Pathology or Dermatopathology Laboratories.
 
Cytokine Assays.
 
Quantitation of IL-4, IL-5, or IL-9 in la-
vage fluid or serum was performed by ELISA using monoclonal
antibodies (PharMingen, San Diego, CA) according to the manu-
facturer’s recommendation. Assays were standardized with re-
combinant murine IL-4 (DNAX, Palo Alto, CA), IL-5 (Phar-
Mingen), or IL-9 (PharMingen). The minimum detectable level
of cytokine in each of the ELISAs was 16 pg/ml (IL-4), 40 pg/ml
(IL-5), and 0.31 ng/ml (IL-9) in lung lavage fluid and 0.62 ng/ml
(IL-9) in serum. For the detection of IL-9 in serum, recombinant
murine IL-9 diluted in mouse serum was used as a positive control.
 
Transmission Electron Microscopy.
 
Lung tissue was prepared for
electron microscopic analysis as previously described (35). In
brief, lung tissue was fixed in 3% glutaraldehyde for a minimum
of 1 h, postfixed in 1% osmium, dehydrated, and embedded in Epox
(Ernest F. Fullam, Inc., Latham, NY). 1-
 
m
 
m-thick sections were
stained with toluidine blue and screened by light microscopy for rep-
resentative areas containing airways. These areas were then selected
for electron microscopy. Thin sections (80 nm) were stained with
uranyl acetate and lead citrate, examined, and photographed with a
Philips 300 electron microscope (Eindhoven, The Netherlands).
 
Histamine Assay.
 
Histamine levels in lavage fluid were deter-
mined using a Histamine-Enzyme Immunoassay Kit (Immuno-
tech, Westbrook, ME) according to the manufacturer’s instruc-
tions. The minimum detectable level of histamine was 0.2 nM for
this assay.
 
Immunohistochemistry.
 
Lungs, completely excised from the
chest, were inflated with a 1:3 dilution of O.C.T. Tissue-Tek
compound (Miles Labs., Inc., Elkhart, IN) in PBS and frozen in
O.C.T. by submersion in 2-methylbutane (Aldrich Chemical
Co., Milwaukee, WI) cooled with dry ice. Tissue sections were
cut, transferred onto silane-treated glass slides, and allowed to dry
at room temperature for 1 h. Sections were fixed in acetone for
10 min and then stored at 
 
2
 
20
 
8
 
C. For staining, sections were re-
hydrated in wash buffer (0.1 M Tris-Cl, pH 7.4, and 0.01%
Triton X-100) for 10 min. Sections were blocked with blocking
buffer (3% BSA, 0.1 M Tris-Cl, pH 7.4, and 0.01% Triton X-100)
for 30 min and with Avidin/Biotin Blocking Kit (Vector Labs.,
Burlingame, CA) for 15 min each before incubation with diluted
biotinylated antibody for 1 h. The sections were then washed
three times for 5 min in wash buffer and incubated with pre-
diluted streptavidin-alkaline phosphatase solution (Kirkegaard and
Perry Labs., Inc., Gaithersburg, MD) for 40 min. The sections
were washed and developed using HistoMark Red Staining Sys-
tem (Kirkegaard and Perry Labs., Inc.) according to the manufac-
turer’s instructions. The slides were counterstained with Meyer’s
hematoxylin and then mounted using Permount (Fisher Scientific
Co., Fairlawn, NJ).
For staining of lung sections, monoclonal antibodies, biotiny-
lated anti–mouse CD4 and CD8a (PharMingen), biotin-conju-
gated anti–mouse B220 (Caltag Labs., San Francisco, CA), and
biotin-conjugated anti–mouse Mac-1 (Serotec, Inc., Raleigh,
NC) were used at appropriate dilutions in 1% BSA/wash buffer.
 
Flow Cytometric Analysis.
 
To detect cytokine production at a
single cell level, intracellular staining for IL-4 and INF-
 
g
 
 was per-
formed according to a modified protocol described elsewhere
(36). In brief, cells retrieved by lung lavage as described above
were washed and cultured at a concentration of 5 
 
3 
 
10
 
6
 
 in the
presence of 0.05 
 
m
 
g/ml PMA (Sigma Chemical Co., St. Louis,
MO) and 0.5 
 
m
 
g/ml ionomycin (Calbiochem Corp., La Jolla,
CA) for 6 h. After 2 h of incubation, monensin (PharMingen)
was added to a final concentration of 2 
 
m
 
M. Cells were washed
once in staining buffer (1
 
3 
 
PBS, 1% FBS, and 0.1% sodium
azide, pH 7.4) and incubated with monoclonal antibodies for the
detection of cell surface markers diluted in staining buffer con-
taining Fc-Block (PharMingen) for 30 min at 4
 
8
 
C. Cells were
washed once in staining buffer and then fixed in PBS containing
4% paraformaldehyde for 30 min at 4
 
8
 
C. Cells were washed twice
in staining buffer and incubated with monoclonal antibodies for
the detection of intracellular cytokines diluted in permeabiliza-
tion buffer (0.1% saponin/staining buffer) containing Fc-Block
for 30 min at 4
 
8
 
C. Cells were washed twice in staining buffer and 
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kept at 4
 
8
 
C in the dark until analysis by FACScan
 
Ò
 
 using
CellQuest (Becton Dickinson, San Jose, CA). Murine Th1 and
Th2 cell clones, producing either INF-
 
g
 
 or IL-4 (37), were used
as a positive control for intracellular cytokine production. Nega-
tive controls consisted of isotype-matched, directly conjugated,
nonspecific antibodies (PharMingen).
For the detection of cell surface markers, Cy-Chrome–conju-
gated monoclonal antibodies (anti–mouse CD4, anti–mouse
CD8a; PharMingen) were used, and for intracellular cytokine
staining, FITC-conjugated anti–mouse INF-
 
g
 
 and PE-conju-
gated anti–mouse IL4 (PharMingen) were used.
 
Physiologic Assessment.
 
Mice were assessed physiologically by
an investigator blinded to the genotype of the mice, using a
method for the determination of airway baseline resistance and
hyperresponsiveness to inhaled methacholine described elsewhere
(34). Mice were anesthetized by intraperitoneal injection of pento-
barbital (90 mg/kg) and tracheostomized with an 18-gauge angio-
catheter (Baxter Scientific, McGraw Park, IL). Airway resistance
was then measured using the modifications of the techniques of
Martin et al. (38). In these assessments, changes in the lung vol-
ume of anesthetized and tracheostomized mice were measured ple-
thysmographically by determining pressure in a plexiglass cham-
ber using an in-line microswitch pressure transducer. Flow was
measured by differentiation of the volume signal, and transpul-
monary pressure was determined by a second microswitch pres-
sure transducer placed in line with the plethysmograph and an an-
imal ventilator. Resistance was then calculated using the method
of Amdur and Mead (39). Resistance of the tracheostomy cathe-
ter was eliminated and baseline measurements of pulmonary resis-
tance were obtained by ventilating the mouse in the plethysmo-
graph at volumes of 0.4 ml at a rate of 150 breaths/min, which
has been shown previously to produce normal arterial blood gases
(38). Each mouse was studied at baseline. Bronchial hyperrespon-
siveness was then determined by methacholine challenge as previ-
ously described (34). Increasing concentrations of methacholine
in PBS were administered by nebulization (20 1-ml breaths), and
pulmonary resistance was calculated precisely 60 s later. Stepwise
increases in methacholine dose were then given until the pulmo-
nary resistance had at least doubled in comparison with the base-
line level. The data are expressed as the provocative challenge
100 (PC100), the dose of methacholine at which pulmonary re-
sistance was 100% above baseline level.
 
Statistical Analysis.
 
Values are expressed as means 
 
6
 
 SD. The
data were normally distributed, and group means were compared
with Student’s two tailed, unpaired 
 
t
 
 test using Excel 5 for Apple
Macintosh (Microsoft Corporation, Redmond, WA). 
 
P 
 
, 
 
0.05
was considered significant.
 
Results
 
Generation of Transgenic Mice.
 
We constructed several in-
dependent lines of transgenic mice in which the expression
of the murine IL-9 cDNA was under the control of the rat
Clara cell protein, CC10, promoter. Previous studies in
mice had demonstrated by chloramphenicol acetyltrans-
ferase expression assay (40), RNase protection assay (33),
and Northern blot analysis (41) that expression regulated by
the CC10 promoter is selective to lung tissue. Of 29 origi-
nal progeny screened by Southern blot analysis and con-
firmed by PCR analysis of tail DNA, 9 animals (31%) were
positive for the CC10 transgene. All founder animals were
backcrossed with B10.D2 mice. Based upon the range of
IL-9 expression levels, four independent lines, 9, 16, 20,
and 25, were chosen for a more detailed analysis.
 
Assessment of IL-9 Levels within Lung and Serum.
 
The ex-
pression of IL-9 in the lung was assessed by mIL-9 levels in
lung lavage fluid by ELISA (Fig. 1). Lower levels of IL-9
were detected in lavage fluid from transgene-positive mice
of lines 16 (4.7 
 
6
 
 3.3 ng/ml) and 20 (19.4 
 
6
 
 11.1 ng/ml),
and higher levels in transgene-positive mice of lines 9 (38.2 
 
6
 
18.7 ng/ml) and 25 (36.8 
 
6
 
 16.3 ng/ml). The levels of IL-9
were below the detection limit (
 
,
 
0.31 ng/ml) in lung la-
vage fluid from transgene-negative mice of all four indepen-
dent lines. IL-9 was not detectable in serum of transgene-
positive or -negative animals (
 
,
 
0.62 ng/ml). Lung lavage
fluid from mice expressing IL-9 did not contain detectable
levels of IL-4 (
 
,
 
16 pg/ml) or IL-5 (
 
,
 
40 pg/ml).
 
Cellular Constituents of Lung Lavage Fluid.
 
Analysis of lung
lavage fluid from IL-9–expressing mice revealed the pres-
ence of inflammatory cells. The total number of cells re-
Figure 1. IL-9 levels in bron-
choalveolar lavage fluid (BALF).
Transgene-positive animals
(TG1) from four independent
lines (9, 16, 20, and 25) expressed
different amounts of IL-9. Each
column represents the mean 6
SD of three representative ani-
mals. No IL-9 was detectable in
lung lavage fluid from transgene-
negative animals (TG2).
Figure 2. Inflammatory cells in lung lavage fluid. Differential cell counts
were derived from at least 500 cell counts and are presented as percentage of
each cell type from total cells (A) and as total cell numbers (B). Data are the
mean 6 SD of counts from 13 IL-9–expressing mice (black bars) and four
transgene-negative control mice (gray bars) from all four transgenic lines.
The number of eosinophils (E) and lymphocytes (L) were significantly in-
creased in IL-9–expressing mice compared with transgene-negative mice
(P # 0.04 and P , 0.03; B), whereas the number of macrophages (M) was
only slightly but not significantly increased (B). N, neutrophils. 
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trieved was significantly increased in mice that expressed
IL-9 (3.79 
 
6
 
 2.98 
 
3 
 
10
 
6
 
,
 
 n 
 
5 
 
13), compared with the
number in transgene-negative mice that did not express IL-9
(0.35 
 
6
 
 0.46 
 
3 
 
10
 
6
 
,
 
 n 
 
5 
 
4;
 
 P 
 
, 
 
0.04). Differential counts
on lung lavage cells revealed a great increase in the number
of eosinophils along with substantial accumulations of lym-
phocytes (Fig. 2, 
 
A
 
 and 
 
B
 
). In contrast, in transgene-nega-
tive animals the majority of cells were macrophages (Fig. 2,
 
A
 
 and 
 
B
 
). Neutrophils were not identified in lung lavage
fluid from transgene-positive and -negative animals (Fig. 2,
 
A
 
 and 
 
B
 
, respectively).
 
Histologic Assessment of Lung Tissue.
 
Examination of lung
tissue stained with hematoxylin and eosin by light micros-
copy revealed the same impressive histologic changes in the
lungs of all IL-9–expressing mice from four independent
lines (Fig. 3, 
 
B
 
–
 
D
 
), which were not observed in lung tissue
from transgene-negative control mice (Fig. 3 
 
A
 
).
Infiltration of lung tissue with mononucleated as well as
multinucleated inflammatory cells occurred around airways
and blood vessels of different sizes (Fig. 3, B and C). A
higher cellularity was also noted within the lung paren-
chyma with the appearance of large macrophages and accu-
mulations of mononuclear cells in areas of high infiltration
(Fig. 3 D) Histologic analysis of the airways from IL-9–
expressing mice revealed that the epithelium from most
conducting airways was hypertrophic (Fig. 3, B and C).
Many epithelial cells seemed to be enlarged due to the ac-
cumulation of material that appeared homogenous within
the cytoplasm that stained positively for mucin with alcian
blue/periodic acid–Schiff (Fig. 4 B). Higher magnification
Figure 3. Lung histology of conducting airways and parenchyma. Sections of formalin-fixed lung tissue from a transgene-negative control mouse (A)
and an IL-9–expressing mouse of line 9 (B–D) were stained with hematoxylin and eosin before examination by light microscopy. Lung sections from
IL-9–expressing mice revealed the presence of inflammatory cells in the subepithelium of conducting airways of all different sizes, smaller airways (B) and
larger airways (C), and around blood vessels, which was not seen in sections from transgene-negative mice (A). The airway epithelium was hypertrophic
(B and C, arrows) compared with that in transgene-negative animals (A). Cellular infiltrations in the lung parenchyma from IL-9–expressing mice were
often associated with nodule-like accumulations of mononuclear cells and large macrophages (D, arrows). Original magnification, A–D: 3250.1311 Temann et al.
Figure 4. Histologic staining for mucin and collagen in lung sections. Light micrographs of formalin-fixed tissue from a transgene-negative control
mouse (A and D) and an IL-9–expressing mouse (B, C, E, and F) stained with alcian blue/periodic acid-Schiff (A–C) or Masson’s trichrome (D–F). The
hypertrophic airway epithelium in sections from IL-9–expressing mice stained positively (magenta) for mucins with alcian blue/periodic acid–Schiff (B).
Higher magnification of the epithelium revealed that only nonciliated epithelial cells but not ciliated cells (arrows) were hypertrophic and stained positive
for mucin (C). The airway epithelium in sections from transgene–negative mice did not stain for mucin (A). Lung sections stained with Masson’s
trichrome demonstrated that thickening of the airway wall in IL-9–expressing mice is associated with increased deposition of material staining positively
(blue) for collagen (E), which was not present in transgene-negative mice (D). A higher magnification of the same area demonstrates extracellular,
intensely blue staining collagen adjacent to inflammatory cells around airway and blood vessel (F). Original magnifications: A, B, and F, 3500; C,
31,000; D and E, 3250.1312 IL-9 Induces Airway Inflammation and Airway Hyperresponsiveness
of the stained epithelium showed that accumulation of mu-
cin-like material appeared in nonciliated but not ciliated
epithelial cells (Fig. 4 C). In contrast, airway epithelia were
not hypertrophic and did not stain positively for mucin
with alcian blue/periodic acid–Schiff in lung sections from
transgene-negative mice (Fig. 4 A).
Masson’s trichrome staining of lung tissue demonstrated
that infiltration around the airways in IL-9–expressing mice
was often accompanied by an increased deposition of collagen
in the subepithelial region (Fig. 4, E and F), which was not
found in airways of transgene-negative animals (Fig. 4 D).
Blood vessels of all different sizes in lungs from IL-9–
expressing mice showed thickening of their walls due to mild
medial hypertrophy as demonstrated in van Gieson–stained
sections (Fig. 5 B). This was not observed in lung sections
of transgene-negative animals (Fig. 5 A). Immunostaining
of lung sections from IL-9–expressing mice for a-smooth
muscle actin demonstrated that hypertrophy was due at
least in part to marked muscle cell proliferation in the me-
dia with migration into the intima (Fig. 5 D). Staining for
smooth muscle actin was much less intensive in lung sec-
tions from transgene-negative mice (Fig. 5 C).
One of the most striking histologic findings in the air-
ways of IL-9–expressing mice was the presence of mast
cells within the airway epithelium. Mast cells were detected
in epithelial and subepithelial regions of all conducting air-
ways in lung tissue stained with toluidine blue (Fig. 6, B
and C) or using Leder’s chloracetate esterase reaction (Fig.
6 D). As expected, mast cells were not present in airway
epithelia from transgene-negative animals (Fig. 6 A).
Figure 5. Histologic analysis of blood vessels. Blood vessels in van Gieson–stained sections from formalin-fixed lung tissue of an IL-9–expressing
mouse (B) showed medial hypertrophy compared with vessels from a transgene-negative control mouse (A). Immunostaining for a-smooth muscle actin
was strongly positive (brown) in wall and lumen of blood vessels found in sections from an IL-9–expressing mouse (D), which was not observed in blood
vessels from transgene-negative mice (C). Original magnification, A–D, 3500.1313 Temann et al.
Electron Microscopic Examination of Airway Epithelium.
Electron microscopic analysis of the epithelium of con-
ducting airways of the lower respiratory tract from IL-9–
expressing mice confirmed the presence of mast cells (Fig.
7 A) that appeared to be fully granulated (Fig. 7, A and B).
Mast cells were not present in the airway epithelium from
transgene-negative control mice (Fig. 7 C).
Electron micrographs of airway epithelium from IL-9–
expressing mice also demonstrated that only nonciliated
epithelial cells were hypertrophic due to massive accumula-
tions of vacuoles containing a homogenous, low-density
material (Fig. 7 A), confirming the results obtained from al-
cian blue/periodic acid–Schiff–stained epithelium (Fig. 4
C). These vacuoles were not observed in ciliated cells that
were not hypertrophic (Fig. 7 A), nor in any cells of the
airway epithelium from transgene-negative animals (Fig. 7 C).
Histamine Levels within Lung Lavage Fluid. To assess the
potential release of mediators from mast cells within the
airway epithelium from IL-9–expressing mice, lung lavage
fluid was analyzed for histamine. Low levels of histamine
were detected in lung lavage fluid of both IL-9–expressing
mice (1.98 6 0.65 nM) and transgene–negative mice (1.14 6
0.79 nM) of all four independent lines (Fig. 8). The slightly
but not significantly increased histamine levels found in la-
vage fluid of IL-9–expressing mice might be explained by
increased numbers of mast cells in the airway epithelia of
these mice.
Characterization of Infiltrating Cells by Histology and Flow
Cytometry. New vital red staining of lung sections from
IL-9–expressing mice demonstrated that high numbers of
eosinophils were among the infiltrating cells around air-
ways and blood vessels (Fig. 9 A) and within the paren-
Figure 6. Histologic staining for mast cells. Toluidine blue staining of sections from formalin-fixed lung tissue revealed mast cells in the airway epithe-
lium from an IL-9–expressing mouse (B and C) but not in the epithelium from transgene-negative mice (A). Dark blue–stained mast cell granules (arrows)
were present in the epithelium of smaller (B) and larger (C) airways. Higher magnification shows red-stained mast cells (arrow) in the airway epithelium
using Leder’s chloracetate esterase reaction (D). Original magnifications: A and B, 3500; C, 3250; D, 31,000.1314 IL-9 Induces Airway Inflammation and Airway Hyperresponsiveness
chyma. Mononuclear cells were identified and further
characterized by immunostaining of frozen lung sections.
Both CD41 and CD81 lymphocytes were detected among
infiltrating cells (Fig. 9, B and C), whereas B2201 cells
were less present and appeared in clusters (Fig. 9 D). Fur-
thermore, a substantial number of infiltrating cells were
probably macrophages that stained positive for Mac-1 (Fig.
9 E). No cellular infiltrations were detected by either new
vital red staining or immunostaining in lung sections from
transgene-negative animals.
To investigate if the expression of IL-9 leads to selective
infiltration of the lungs with lymphocytes producing either
Th1- or Th2-type cytokines, lung lavage cells from IL-9–
expressing mice were analyzed individually by flow cytom-
etry for the presence of intracellular IL-4 and INF-g. Fig.
10 shows typical dot-plots of IL-4 and INF-g staining in
CD41 (Fig. 10 A) and CD81 (Fig. 10 B) lymphocytes re-
trieved by lung lavage that were present at a 2:1 ratio (data
not shown). The percentage of INF-g–producing cells
among CD41 as well as CD81 lymphocytes was slightly
higher compared with IL-4–producing cells or cells stain-
ing positively for both cytokines (Fig. 10, A and B). None-
theless, there was no selective accumulation of either IL-4
or INF-g–producing CD41 lymphocytes detectable in
lung lavage fluid from IL-9–expressing mice.
Assessment of Lung Physiology. To assess the physiologic
changes associated with lung selective expression of IL-9 in
the airways of transgenic mice, both baseline airway resis-
tance and the bronchial responsiveness to inhaled metha-
choline was determined. Several IL-9–expressing mice had
increased airway resistance at baseline compared with trans-
gene-negative control mice. However, when analyzed as a
group, IL-9–expressing mice exhibited no significant dif-
ference in baseline airway resistance, 0.79 6 0.77 cm
H2O/ml/s (n 5 8), compared with transgene-negative lit-
termates, 0.31 6 0.05 cm H2O/ml/s (n 5 8, P . 0.09)
(Fig. 11 A). Challenge with methacholine showed that IL-
9–expressing mice required a significantly lower dose of
methacholine to achieve a 100% increase in respiratory re-
sistance (PC100), 0.452 6 0.487 (n 5 8), than did trans-
gene-negative littermates, 1.606 6 0.362 (n 5 8, P ,
0.0001) (Fig. 11 B). This difference reflects a 30-fold increase
in airway hyperresponsiveness compared with transgene-
negative littermates. Thus, airway-selective overexpression
of IL-9 in the lungs of transgenic mice resulted in a non-
significant trend toward increased baseline airway resistance
as well as markedly increased airway hyperresponsiveness.
Discussion
Our results strongly support a potential and major role
for IL-9 in the pathogenesis of allergic asthma. Expression
of IL-9 selectively within the lungs of our transgenic mice
caused hypertrophy of airway epithelium, submucosal ac-
cumulation of collagen, cellular infiltrates with eosinophils
and lymphocytes, and mast cell hyperplasia. These mice
also demonstrated the critical physiological response to in-
haled methacholine that is characteristic of patients with
asthma, namely hyperresponsiveness.
Figure 7. Electron micrographs of epithelium from conducting airways
of the lower respiratory tract. Representative area of the airway epithe-
lium from an IL-9–expressing mouse shows that fully granulated mast
cells (MC) were present (A). A higher magnification of mast cell granules
from the same cell as shown in A did not reveal any signs of degranulation
(B).  N,  nucleus,  EDG,  electron-dense granules. Mast cells were not
present in airway epithelium from transgene-negative control mice (C).
Nonciliated epithelial cells (NC) in IL-9–expressing mice were hyper-
trophic and showed accumulations of low-density vacuoles, whereas cili-
ated cells (CI) appeared normal (A). Epithelium from a transgene-nega-
tive mouse shows normal nonciliated (NC) and ciliated (CI) epithelial
cells (C). Bars in A, B, and C represent 1 mm. Original magnifications: A,
35,000; B, 322,400; C, 33,300.
Figure 8. Histamine levels in
lung lavage fluid. IL-9–express-
ing mice (TG1) and transgene
negative mice (TG2) had similar
histamine levels in lung lavage
fluid as determined by enzyme
immunoassay. Levels are ex-
pressed as individual data points
for each mouse (diamonds) and as
means (lines).1315 Temann et al.
Figure 9. Characterization of inflammatory cells in lung sections from an IL-9–expressing mouse. Formalin-fixed tissue was stained with new vital red
to demonstrate that eosinophils were present in high numbers in lung tissue from IL-9–expressing mice (A). Immunostaining of frozen lung sections
(B–E) revealed that cell infiltrates also contained CD41 (B), CD81 (C), B2201 (D), and Mac-11 (E) mononuclear cells. Original magnifications: A,
3600; B–E, 3500.1316 IL-9 Induces Airway Inflammation and Airway Hyperresponsiveness
Genetic studies have linked asthma, atopy, and bronchial
hyperresponsiveness to human chromosome 5q31-q33 (10),
which contains several genes involved in the allergic im-
mune response. The gene for IL-9 is located within that re-
gion (12), and allelic association between IL-9 and total se-
rum IgE levels has been demonstrated (10). Recently,
studies with different inbred strains of mice linked bron-
chial hyperresponsiveness to mouse chromosome 13, which
shares homology with human chromosomal region 5q31-
q33 and on which the murine homologue of the IL-9 gene
is located (14). Correlation between strain-specific mRNA
and protein levels of IL-9 and hyperresponsiveness has been
demonstrated. In particular, these studies have shown that
reduced expression levels of IL-9 were associated with hy-
poresponsiveness (14). Based on these data and on its pleio-
tropic functions, IL-9 was proposed as a critical factor in-
volved in the pathogenesis of asthma (14). Expression of
IL-9 in vivo in the lungs of our transgenic mice resulted in
increased native airway hyperresponsiveness. Thus, the over-
expression of one cytokine, selectively within the lungs,
even in the absence of exposure of these mice to known
antigens, resulted in marked increase in sensitivity to the
bronchoconstrictor agonist. This new finding is in accord
with recently published data (14) suggesting a role for IL-9
in the development of airway hyperresponsiveness.
There appears to be a clear association between airway
hyperresponsiveness that defines asthma and airway inflam-
mation (1). However, the exact mechanism(s) leading to
this altered airway physiology is still unknown. Eosino-
philic and lymphocytic infiltration of the airways is a com-
mon feature of human asthma (42, 43). A similar inflamma-
tory response was seen in the lungs of IL-9–expressing mice
that demonstrated airway hyperresponsiveness to methacho-
line. Eosinophils and lymphocytes were found surrounding
airways and blood vessels and were present in lung lavage
fluid. These findings mimic important histologic character-
istics of human asthma. Several studies have demonstrated a
correlation between the degree of inflammation, in partic-
ular eosinophilia, and airway hyperresponsiveness in asth-
matic patients (44–46). The application of animal models to
the study of experimental atopic asthma has not yet con-
firmed the requirement of eosinophils and their products in
the development of airway hyperresponsiveness, which re-
mains controversial (47–49). For example, studies in mice
have demonstrated that hyperresponsiveness might occur in
the absence of eosinophilic airway inflammation (48, 49).
Therefore, how eosinophils and their products may con-
tribute to the altered human airway physiology typical of
asthma remains to be determined.
Recently, interest has focused on the association be-
tween activated CD41 T lymphocytes, in particular the
Th2 subset, and the pathogenesis of asthma (50–52). It has
been shown that CD41 Th2 cells are present and activated
in the bronchial wall and lavage fluid of atopic asthmatics
(53, 54). IL-4 and IL-5, produced by Th2 cells, have been
postulated to have central roles in the initiation and main-
tenance of allergic inflammation because IL-4 is essential
for sustaining a Th2-type immune response (55), acts on
mast cells and eosinophils (56), and is a critical factor for
IgE isotype switching in B cells (57). IL-5 regulates
growth, differentiation, and activation of eosinophils (58,
59). Expression of either IL-4 or IL-5 in the lungs of trans-
genic mice promoted an impressive inflammatory response
(33, 60). Despite evidence for an important role of these
Th2 cell–derived cytokines in the inflammatory response in
the lungs of asthmatics, proof of direct contributions of
these factors to pathologic and physiologic changes in the
airways of asthmatics has remained elusive. Expression of
IL-9, another Th2 cell–derived cytokine (15), in the lungs
of our transgenic mice also resulted in an impressive in-
flammatory response that showed differences from that ob-
served in IL-4 or IL-5 transgenic mice. Accumulations of
B2201 lymphocytes as found in the lungs of IL-4 trans-
genic mice (Temann, U.-A., unpublished observation) or
Figure 10. Intracellular detection of IL-4 and INF-g in lymphocytes
from lung lavage fluid of IL-9–expressing mice. Data shown are generated
by three-color flow cytometric analysis of total lung lavage cells and
pooled from four IL-9–expressing littermates after short-term culture in
the presence of PMA, ionomycin, and monensin. Dot-blots were gated
on CD41 lymphocytes (A) or CD81 lymphocytes (B). Number of cells
staining for each cytokine are expressed as a percentage of CD41 or
CD81 cells.
Figure 11. Assessment of lung physiology. Two independent experi-
ments were performed to compare airway baseline resistance (A) and air-
way hyperresponsiveness to inhaled methacholine, LOG PC100 (B), in
IL-9–expressing mice (TG1) and in transgene-negative littermates
(TG2). Mice derived from two independent lines, 9 (open diamonds) and
25 (filled diamonds), are expressed as individual data points and as means
(lines).1317 Temann et al.
expansion of bronchus-associated lymphoid tissue, mostly
consisting of B cells, as in IL-5 transgenic mice (60), were
not seen in the lungs of IL-9–expressing mice. Only a mi-
nor population of the infiltrating cells were B2201. Instead,
cell infiltrates seen in the lungs of IL-9–expressing mice,
predominantly eosinophils but also CD41 and CD81 lym-
phocytes, were very similar to those seen in asthmatic
lungs. In human asthma, a predominance of Th2-like lym-
phocytes has been demonstrated in several studies (53, 54).
We show that IL-4 as well as INF-g–producing lympho-
cytes were identified among infiltrating cells in lung lavage
fluid after short-term stimulation in vitro, which suggests
that local expression of IL-9 alone does not lead to a Th2
specificity of the infiltrating CD41 lymphocytes in the
lungs. Interestingly, similar results have recently been pub-
lished on lung lavage cells from allergic asthmatics (61),
demonstrating that only a smaller portion of T cells are
producing IL-4 while the majority produces INF-g.
Therefore, the postulated predominantly Th2-regulated
immune response in allergic asthma remains controversial.
Overexpression of IL-9 in the lungs of our transgenic
mice resulted in certain, important pathologic and physio-
logic changes characteristic of human asthma. These in
vivo  findings support a new and important central role for
IL-9 in the pathogenesis of asthma. Also of interest is that
other typical features of human asthma, such as airway epi-
thelial shedding, mucus plugs, or airway smooth muscle
hypertrophy, were not observed in IL-9–expressing mice
used in this study. Furthermore, the vascular changes seen
in the lungs of IL-9–expressing mice are not typical of hu-
man asthma. The observed medial hypertrophy in vessel
walls that are due, at least in part, to smooth muscle cell
proliferation are histologic changes seen more commonly
in primary pulmonary hypertension (62).
An important new finding that distinguishes IL-9 trans-
genic mice from those expressing other Th2 cytokines se-
lectively within the lungs was the presence of mast cells in
the airway epithelium of all conducting airways. Mast cells
are important in immediate allergic responses and acute
bronchoconstriction. Cross-linking of allergen-specific IgE
bound to high affinity receptors FceRI on the surface of
mast cells by antigen leads to activation and secretion of a
wide variety of mediators causing direct bronchoconstric-
tion and enhancement of airway inflammation (63, 64). In
the human lung, mast cells are located in the trachea, mucosa,
and submucosa of all airways and within the parenchyma
(65). Their number is increased in the lungs of asthmatics
compared with nonasthmatics, and they often exhibit signs
of degranulation (66). In contrast, mast cells are sparse in
the murine lung and only limited numbers are present in the
tracheal tissue. Mast cells were detected in great numbers in
the airway epithelium of our IL-9–expressing mice. The
presence of fully granulated mast cells in the airway epithe-
lium demonstrated by electron microscopic analysis as well
as similar histamine levels in lung lavage fluid from IL-9–
expressing mice and transgene-negative control mice sug-
gest no significant mast cell degranulation with release of
mediators. However, whether or not these mast cells play a
role in the development of the observed phenotype in IL-
9–expressing mice is still not completely elucidated. A fur-
ther characterization of these mast cells, especially for their
protease phenotype, may allow a more specific assessment
of the potential contributions these cells may make to
pathologic and physiologic changes in the lungs of IL-9–
expressing mice. IL-9 is known to promote growth and
differentiation of mast cells in vitro (28, 29) and in vivo
(67). Therefore, the presence of mast cells in the airway ep-
ithelium from IL-9–expressing mice seems to be a direct
effect of IL-9, since mast cell hyperplasia in the airway epi-
thelium has not been described in transgenic mice express-
ing other Th2 cytokines, IL-4, IL-5, or IL-6 selectively
within their lungs (33, 60, 34). Our observations in vivo
support the function of IL-9 as a primary growth and dif-
ferentiation factor of mast cells. They further suggest that
mast cells are recruited to, or proliferate and differentiate
in, the airways of asthmatics as a consequence of IL-9 pro-
duced locally within the lungs by activated Th2 lympho-
cytes. Our data provide functional evidence for a potential
important role of IL-9 in the pathogenesis of asthma.
We propose that IL-9 derived from CD41 Th2 cells may
play an important role in inflammatory responses in the
lung and potentially contributes to both pathologic and
physiologic changes characteristic of the asthmatic airway.
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